Discontinued — last reported Q4 '25
D&A
OperatingEli Lilly D&A increased by 24.6% to $585.70M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 20.8%, from $484.80M to $585.70M. Over 4 years (FY 2021 to FY 2025), D&A shows an upward trend with a 6.6% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2007
Last reportedQ4 2025
How to read this metric
Higher values often reflect significant historical capital expenditures or acquisitions that are now being expensed over time.
Detailed definition
A non-cash accounting expense that spreads the cost of tangible and intangible assets over their useful lives. This amou...
Peer comparison
Capital-intensive tech companies with large data center footprints typically show high D&A relative to revenue.
Metric ID:
cf_depreciation_and_amortizationHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $369.30M | $382.30M | $445.70M | $435.70M | $348.90M | $362.90M | $375.00M | $362.30M | $366.30M | $411.00M | $387.70M | $400.60M | $414.40M | $466.80M | $484.80M | $462.80M | $478.50M | $470.00M | $585.70M |
| QoQ Change | — | +3.5% | +16.6% | -2.2% | -19.9% | +4.0% | +3.3% | -3.4% | +1.1% | +12.2% | -5.7% | +3.3% | +3.4% | +12.6% | +3.9% | -4.5% | +3.4% | -1.8% | +24.6% |
| YoY Change | — | — | — | — | -5.5% | -5.1% | -15.9% | -16.8% | +5.0% | +13.3% | +3.4% | +10.6% | +13.1% | +13.6% | +25.0% | +15.5% | +15.5% | +0.7% | +20.8% |
Range$348.90M – $585.70M
CAGR+10.8%
Avg YoY Growth+6.2%
Median YoY Growth+10.6%
Business Segments
Loading segment data...
D&A at Other Companies
Frequently Asked Questions
- What is Eli Lilly's d&a?
- Eli Lilly (LLY) reported d&a of $585.70M in Q4 2025.
- How has Eli Lilly's d&a changed year-over-year?
- Eli Lilly's d&a increased by 20.8% year-over-year, from $484.80M to $585.70M.
- What is the long-term trend for Eli Lilly's d&a?
- Over 4 years (2021 to 2025), Eli Lilly's d&a has grown at a 6.6% compound annual growth rate (CAGR), from $1.55B to $2.00B.
- What does d&a mean?
- An accounting adjustment that adds back the cost of wear and tear on equipment and software.